T cell therapy of Epstein-Barr virus and adenovirus infections after hemopoietic stem cell transplant.
Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disease (PTLD) and adenovirus (AdV)-related pathologies are life-threatening complications of immunosuppression in recipients of hematopoietic stem cell transplantation (HSCT). In certain cohorts (unrelated and haploidentical donor HSCT, T-cell-depleted allograft), the risk of developing these complications is higher. Here we describe the impact of T cell therapy, within programs of specific routine surveillance and preemptive treatment, on the course of EBV infection, and development of related disease, in pediatric recipients of T-cell-depleted, HLA-haploidentical HSCT. Future prospectives include the transfer of this technology to treat AdV-related complications following HSCT.
Comoli
P
P
Pediatric Hematology/Oncology, and Virology Service, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Viale Golgi 19, 27100 Pavia, Italy. pcomoli@smatteo.pv.it
Basso
S
S
Labirio
M
M
Baldanti
F
F
Maccario
R
R
Locatelli
F
F
D000257:Adenoviridae Infections / Q000276:immunology / Q000628:therapy*; D019264:Adoptive Transfer / Q000379:methods*; D000956:Antigens, Viral / Q000276:immunology; D020031:Epstein-Barr Virus Infections / Q000276:immunology / Q000628:therapy*; D006239:Haplotypes; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006650:Histocompatibility Testing; D006801:Humans; D008212:Lymphocyte Depletion; D009894:Opportunistic Infections; D037182:T-Cell Antigen Receptor Specificity; D013602:T-Lymphocytes, Cytotoxic / Q000166:cytology / Q000276:immunology / Q000637:transplantation*; D016896:Treatment Outcome
D000956:Antigens, Viral